Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer, Xeris uses these filings to report financial results, describe product performance for Recorlev, Gvoke, and Keveyis, and update investors on developments in its pipeline and technology platforms, including XP-8121 and the XeriSol and XeriJect technologies.
Key documents for XERS include current reports on Form 8-K, which Xeris uses to furnish press releases detailing quarterly and year-to-date results, revenue by product, cost of goods sold, research and development spending, selling, general and administrative expenses, and non-GAAP measures such as Adjusted EBITDA. These filings also summarize business highlights, such as changes in demand across the company’s commercial products, updates to revenue guidance, and commentary on investments in Recorlev commercialization and pipeline advancement.
In addition to 8-Ks, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q for a more comprehensive view of Xeris’ business, including risk factors, segment information, and detailed financial statements. Proxy statements and other filings can provide information on governance and compensation, while ownership and insider transaction reports on forms such as Form 4 can show equity awards and trading activity by directors and officers.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, product performance, and key disclosures without reading every page. Real-time updates from EDGAR help ensure that new XERS filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 reports, are available as they are posted, giving investors a structured way to review Xeris’ regulatory history and ongoing reporting.